Skip Navigation

European Heart Journal 1990 11(10):876-884;
Copyright © 1990 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by VIRK, S. J. S.
Right arrow Articles by DAVIES, M. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VIRK, S. J. S.
Right arrow Articles by DAVIES, M. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 The European Society of Cardiology

The effects of the partial beta1-agonist xamoterol on heart rate and ventricular arrhythmias in patients with mild to moderate heart failure

S. J. S. VIRK, N. H. ANFILOGOFF, N. LAWSON, F. QIANG, R. G. MURRAY, W. A. LITTLER and M. K. DAVIES

Department of Cardiovascular Medicine, University of Birmingham East Birmingham Hospital, Birmingham, U. K.

Received 25 September 1989; revised 18 January 1989; .

Correspondence. Dr S. J. S. Virk, University Department of Cardiovascular Medicine. Queen Elizabeth Hospital, Edgbaston, Birmingham B15 2TH, U. K.

Abstract

A major concern with the use of oral inotropes in chronic heart failure is their propensity to exacerbate cardiac arrhythmias. In a double-blind randomized placebo-controlled crossover study of xamoterol, a novel beta1-partial agonist, 24 h ambulatory electrocardiograms were obtained in 26 patients prior to and at the end of 13-week treatment periods. During treatment with xamoterol there was no significant change in mean hourly number of ventricular extrasystoles compared with baseline and placebo (30 ± 17 vs 56 ± 42 and 18± 7, respectively), or in the number of patients showing complex forms (multiform VEs, pairs, ventricular tachycardia) (20/26 vs 19/26 and 19/26, respectively), or ventricular tachycardia alone (5/26 vs 4/26 and 6/26, respectively).

Xamoterol therapy also stabilized heart rate variability over the 24 h period.

Key Words: Xamoterol • heart rate • ventricular arrhythmias • heart failure • beta1-adrenoceptor partial agonist • beta-adrenoceptor blockade • 24 h ambulatory electrocardiography


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.